Anti-IFNAR2 antibody,Abcam,AB104451

Target data Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) (PubMed : 10049744, PubMed : 10556041, PubMed : 21854986, PubMed : 26424569, PubMed : 28165510, PubMed : 32972995, PubMed : 7665574, PubMed : 7759950, PubMed : 8181059, PubMed : 8798579, PubMed : 8969169). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response (PubMed : 10049744, PubMed : 17517919, PubMed : 21854986, PubMed : 26424569, PubMed : 28165510, PubMed : 32972995, PubMed : 7665574, PubMed : 7759950, PubMed : 8181059, PubMed : 8798579, PubMed : 8969169). Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another (PubMed : 10556041, PubMed : 11682488, PubMed : 12105218, PubMed : 21854986, PubMed : 32972995). The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (STAT1, STAT2 and STAT) (PubMed : 11682488, PubMed : 12105218, PubMed : 21854986, PubMed : 32972995). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes (PubMed : 12105218, PubMed : 28165510, PubMed : 9121453).. Isoform 3. Potent inhibitor of type I IFN receptor activity. See full target information IFNAR2